Gestational diabetes & diabetes in pregnancy
Real‐world use of Control‐IQ™ technology automated insulin delivery in pregnancy: A case series with qualitative interviews
Authors' conclusion
Early adopters of Control-IQ technology safely used this system off-label in pregnancy and reported reduced diabetes management burden and improved sleep. The largest glycaemic improvements were observed among those with the lowest pregnancy time-in-range glucose at the beginning of pregnancy. Participants with low pregnancy glucose time-in-range increased their time-in-range with Control-IQ technology use and participants with high pregnancy glucose time-in-range maintained and increased their time-in-range with less diabetes management burden.
Study context
- Population
- Early adopters of Tandem t:slim X2 pump with Control-IQ technology automated insulin delivery (AID) in pregnancy and postpartum
- Participants
- 4 early adopters
- Exposure
- Case 1 vs Cases 2-4
- Outcome
- Pregnancy glucose TIR (3.5-7.8 mmol/L [63-140 mg/dL])
- Follow-up
- First to third trimester
Methodological detailsreal-world, off-label use
- Real-world
- Off-label use
Main finding
As reported in the abstract
- Case 1: TIR increased by third trimester
- 58.7% to 73.3%
- Cases 2-4: TIR increased between first and third trimesters, respectively
- 73.4% to 78.7%, 78% to 83.6%, and 46.5% to 71.9%
- Mid-pregnancy decline in TIR (suboptimal pump setting adjustments, delayed sensor and infusion set replacement)
- two of the four participants
Observational data: associations, not effects.
Further findings
Qualitative experiences
- All participants reported reduced diabetes management burden and improved sleep with Control-IQ technology use
Safety
- No DKA or severe hypoglycaemia occurred
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →